Trademark: 87765139
Word
EBI EXPONENTIAL BIOTHERAPIES
Status Date
Tuesday, March 29, 2022
Registration Number
6681763
Registration Date
Tuesday, March 29, 2022
Filing Date
Monday, January 22, 2018
Published for Opposition
Tuesday, January 11, 2022
40 custom manufacture of medicines, pharmaceutical drugs, biopharmaceutical drugs, pharmaceuticals and biopharmaceuticals; treatment of biopharmaceutical and pharmaceutical materials being medicines, biopharmaceutical and pharmaceutical compounds, synthetic peptides and synthetic peptidomimetics; processing of medicines, biopharmaceutical and pharmaceutical compounds, synthetic peptides and synthetic peptidomimetics for others; custom manufacture of medical devices for others
5 medicines, namely, medicines for alleviating or treating vasculogenic disease, medicines for alleviating or treating hemodynamic instabilities, medicines for alleviating or treating diabetes, medicines for alleviating or treating of immune system related diseases and disorders; pharmaceutical drugs, namely, pharmaceutical preparations for alleviating or treating vasculogenic disease, pharmaceutical preparations alleviating or treating hemodynamic instabilities, pharmaceutical preparations for alleviating or treating diabetes, pharmaceutical preparations for alleviating or treating of immune system related diseases and disorders; biopharmaceutical drugs, namely, biopharmaceutical preparations for alleviating or treating vasculogenic disease, biopharmaceutical preparations for alleviating or treating hemodynamic instabilities, biopharmaceutical preparations for alleviating or treating diabetes, biopharmaceutical preparations for alleviating or treating of immune system related diseases and disorders; biopharmaceuticals, namely, biopharmaceuticals for alleviating or treating vasculogenic disease, biopharmaceuticals alleviating or treating hemodynamic instabilities, biopharmaceuticals for alleviating or treating diabetes, biopharmaceuticals for alleviating or treating of immune system related diseases and disorders; synthetic peptides for biopharmaceutical purposes and for pharmaceutical purposes, namely, synthetic peptides for alleviating or treating vasculogenic disease, synthetic peptides for alleviating or treating hemodynamic instabilities, synthetic peptides for alleviating or treating diabetes, synthetic peptides for alleviating or treating of immune system related diseases and disorders; synthetic peptidemimetics for biopharmaceutical purposes and for pharmaceutical purposes, namely, sytnthetic peptidomimetics for alleviating or treating vasculogenic disease, synthetic peptidomimetics for alleviating or treating hemodynamic instabilities, synthetic peptidomimetics for alleviating or treating diabetes, synthetic peptidomimetics for alleviating or treating of immune system related diseases and disorders
42 biopharmaceutical and pharmaceutical research; conducting clinical trials for others in the fields of medicines, synthetic peptides and synthetic peptidomimetics as they relate to use as an ingredient in medicines, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; scientific research of medicines, synthetic peptides and synthetic peptidomimetics as they relate to use as an ingredient in medicines, biopharmaceuticals and pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; development, testing, and inspection of medicines, synthetic peptides and synthetic peptidomimetics as they relate to use as an ingredient in medicines, pharmaceutical drugs, biopharmaceutical drugs, pharmaceuticals and biopharmaceuticals; laboratory services relating to medicines, synthetic peptides, synthetic peptidomimetics, pharmaceutical drugs, biopharmaceutical drugs, pharmaceuticals and biopharmaceuticals, namely, research in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; laboratory analysis in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; medical research in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; scientific research for medical purposes in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs
The mark consists of a broken circle comprised of a curved red band and a curved gray band. A red triangle appears in the middle of the left band and protrudes into the circle. Within the left side of the circle are two gray polygons of triangular shape with curved corners and lines. To the right of this circular design are the letters "EBI" appearing in a large gray font with the wording "EXPONENTIAL BIOTHERAPIES" appearing in a smaller gray font below.
The red and gray are claimed as a feature of the mark.
"BIOTHERAPIES"
Mar 29, 2022
Registered-Principal Register
Jan 11, 2022
Official Gazette Publication Confirmation E-Mailed
Jan 11, 2022
Published For Opposition
Dec 22, 2021
Notification Of Notice Of Publication E-Mailed
Dec 7, 2021
Law Office Publication Review Completed
Dec 2, 2021
Approved For Pub - Principal Register
Dec 2, 2021
Examiner's Amendment Entered
Dec 2, 2021
Notification Of Examiners Amendment E-Mailed
Dec 2, 2021
Examiners Amendment E-Mailed
Dec 2, 2021
Examiners Amendment -Written
Nov 29, 2021
Previous Allowance Count Withdrawn
Nov 9, 2021
Withdrawn From Pub - Og Review Query
Oct 25, 2021
Law Office Publication Review Completed
Oct 16, 2021
Approved For Pub - Principal Register
Oct 13, 2021
Teas/Email Correspondence Entered
Oct 13, 2021
Correspondence Received In Law Office
Oct 13, 2021
Teas Request For Reconsideration Received
Oct 12, 2021
Notification Of Final Refusal Emailed
Oct 12, 2021
Final Refusal E-Mailed
Oct 12, 2021
Final Refusal Written
Oct 1, 2021
Previous Allowance Count Withdrawn
Oct 1, 2021
Withdrawn From Pub - Senior Attorney Request
Oct 1, 2021
Approved For Pub - Principal Register
Sep 1, 2021
Teas/Email Correspondence Entered
Sep 1, 2021
Correspondence Received In Law Office
Sep 1, 2021
Teas Response To Office Action Received
Mar 1, 2021
Notification Of Non-Final Action E-Mailed
Mar 1, 2021
Non-Final Action E-Mailed
Mar 1, 2021
Non-Final Action Written
Feb 18, 2021
Teas/Email Correspondence Entered
Feb 18, 2021
Correspondence Received In Law Office
Feb 17, 2021
Assigned To Lie
Feb 11, 2021
Teas Response To Suspension Inquiry Received
Oct 1, 2020
Notification Of Letter Of Suspension E-Mailed
Oct 1, 2020
Letter Of Suspension E-Mailed
Oct 1, 2020
Suspension Letter Written
Sep 11, 2020
Teas/Email Correspondence Entered
Sep 11, 2020
Correspondence Received In Law Office
Sep 4, 2020
Teas Response To Suspension Inquiry Received
Aug 18, 2020
Notification Of Inquiry As To Suspension E-Mailed
Aug 18, 2020
Inquiry To Suspension E-Mailed
Aug 18, 2020
Suspension Inquiry Written
Aug 4, 2020
Suspension Checked - To Attorney For Action
Jan 9, 2020
Notification Of Letter Of Suspension E-Mailed
Jan 9, 2020
Letter Of Suspension E-Mailed
Jan 9, 2020
Suspension Letter Written
Dec 26, 2019
Teas/Email Correspondence Entered
Dec 26, 2019
Correspondence Received In Law Office
Dec 19, 2019
Assigned To Lie
Dec 16, 2019
Teas Response To Suspension Inquiry Received
Jun 15, 2019
Notification Of Inquiry As To Suspension E-Mailed
Jun 15, 2019
Inquiry To Suspension E-Mailed
Jun 15, 2019
Suspension Inquiry Written
Jun 11, 2019
Suspension Checked - To Attorney For Action
Nov 20, 2018
Notification Of Letter Of Suspension E-Mailed
Nov 20, 2018
Letter Of Suspension E-Mailed
Nov 20, 2018
Suspension Letter Written
Nov 10, 2018
Teas/Email Correspondence Entered
Nov 9, 2018
Correspondence Received In Law Office
Nov 9, 2018
Teas Response To Office Action Received
May 9, 2018
Notification Of Non-Final Action E-Mailed
May 9, 2018
Non-Final Action E-Mailed
May 9, 2018
Non-Final Action Written
May 2, 2018
Assigned To Examiner
Feb 8, 2018
Preliminary/Voluntary Amendment - Entered
Feb 7, 2018
Assigned To Lie
Feb 3, 2018
Notice Of Design Search Code E-Mailed
Feb 2, 2018
New Application Office Supplied Data Entered
Jan 30, 2018
Teas Voluntary Amendment Received
Jan 25, 2018
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
